Table 3.
Summary of disease outcomes of the two SARS-CoV-2 variant groups stratified by vaccination status.
| Infection among veterans without booster (≥14 days of 2nd dose and <14 days post 3rd dose) |
Infection among veterans with booster (≥ 14 days of 3rd dose) |
|||||
|---|---|---|---|---|---|---|
| Omicron N = 7,466 |
Delta N = 7,952 |
P-value | Omicron N = 910 |
Delta N = 403 |
P-value | |
| N (%) | N (%) | N (%) | N (%) | |||
| Outcome-disease status | ||||||
| Mild | 6760 (90.5) | 6826 (85.8) | 2.2 × 10−16 | 849 (93.3) | 345 (85.6) | 1.233 × 10 −5 |
| Moderate | 451 (6.0) | 572 (7.2) | 44 (4.8) | 34 (8.4) | ||
| Severe-critical | 255 (3.4) | 554 (7.0) | 17 (1.9) | 24 (6.0) | ||
| Moderate or severe | 706 (9.4) | 1126 (14.2) | 2.2 × 10−16 | 48 (5.7) | 58 (14.4) | 1.731 × 10-4 |
Moderate disease: Hospitalized but no intensive care unit admission; Severe/critical disease: intensive care unit admission or death with 28 days of positive test date
Comparisons between groups were performed using Pearson’s X2 tests. A two-sided P-value of < 0.05 was considered to be statistically significant. Adjustments for multiple comparisons were not made.